THE USE OF ROMIPLOSTIM IN AN INFANT

THE USE OF ROMIPLOSTIM IN AN INFANT

Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab...

Full description

Saved in:
Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy Vol. 43; pp. S56 - S57
Main Authors: Fatma Burçin KURTİPEK, Turan BAYHAN, Vildan ÇULHA, Neşe YARALI
Format: Journal Article
Language:English
Published: Elsevier 01-11-2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.
ISSN:2531-1379
DOI:10.1016/j.htct.2021.10.1072